Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Public ClinicalTrials.gov record NCT00606632. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)
Study identification
- NCT ID
- NCT00606632
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Heidelberg Pharma AG
- Industry
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Interventions
- 124-Iodine-cG250 (124I-cG250) Drug
- CT Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2008
- Primary completion
- Oct 31, 2009
- Completion
- Nov 30, 2009
- Last update posted
- Oct 1, 2018
2008 – 2009
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Geffen School of Medicine, UCLA | Los Angeles | California | 90095-1721 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| H. Lee Moffitt Cancer Center & Research Center | Tampa | Florida | 33612 | — |
| Lahey Clinic | Burlington | Massachusetts | 01805 | — |
| University of Michigan | Ann Arbor | Michigan | 48109-0330 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| UNC School of Medicine-Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center | Durham | North Carolina | 27711 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19104-4283 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104-4283 | — |
| MD Anderson | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00606632, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2018 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00606632 live on ClinicalTrials.gov.